Glenmark Life Sciences Limited

Equities

GLS

INE03Q201024

Pharmaceuticals

End-of-day quote NSE India S.E. 03:30:00 16/07/2024 am IST 5-day change 1st Jan Change
855.1 INR +1.17% Intraday chart for Glenmark Life Sciences Limited -3.53% +30.14%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Glenmark Pharmaceuticals to Sell 7.84% Stake in Glenmark Life Sciences MT
Glenmark Pharma to Sell 7.84% Stake in Glenmark Life via Offer for Sale CI
Granules India posts Q4 revenue fall on weak paracetamol sales, price erosion RE
Transcript : Glenmark Life Sciences Limited, Q4 2024 Earnings Call, Apr 25, 2024
Glenmark Life Sciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2024 CI
Glenmark Life Sciences Limited Reports Earnings Results for the Full Year Ended March 31, 2024 CI
Glenmark Life Sciences Limited Announces Resignation of Gita Nayyar as Non-Executive, Independent Director CI
Nirma Limited completed the acquisition of 75% stake in Glenmark Life Sciences Limited from Glenmark Pharmaceuticals Limited. CI
Glenmark Life Sciences Limited Announces Board Resignations, Effective March 6, 2024 CI
Nirma Limited completed the acquisition of 0.000738% stake in Glenmark Life Sciences Limited. CI
India's Glenmark Pharma posts loss for Q3 as remediation cost weighs RE
Transcript : Glenmark Life Sciences Limited, Q3 2024 Earnings Call, Jan 24, 2024
India's Glenmark Life Sciences posts Q3 profit rise; strong orderbook ahead, says CEO RE
Glenmark Life Sciences Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Paracetamol maker Granules India posts marginal rise in Q3 profit RE
Glenmark Life Signs Master Supply Agreement with Japanese Drugmaker for Urinary Anti-Spasmodic API MT
Glenmark Life Sciences Announces Another CDMO Deal CI
India's Glenmark Pharma posts Q2 loss on exceptional legal costs RE
Paracetamol maker Granules India's Q2 revenue rises on higher N.America demand RE
Transcript : Glenmark Life Sciences Limited, Q2 2024 Earnings Call, Oct 20, 2023
India's Glenmark Life Sciences posts Q2 profit rise on API boost RE
Glenmark Life Sciences Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Glenmark Life Sciences Limited Declares Interim Equity Dividend for the Financial Year 2023-24, Payable on or After October 23, 2023 CI
Indian paracetamol maker Valiant Laboratories lists at 16% premium RE
Glenmark Life Sciences Limited Approves Interim Dividend for the Financial Year 2022-23 CI
Chart Glenmark Life Sciences Limited
More charts
Glenmark Life Sciences Limited is an India-based developer and manufacturer of non-commoditized, active pharmaceutical ingredients (APIs) in chronic therapeutic areas. The Company is providing contract development and manufacturing (CDMO) services to a range of multinational and specialty pharmaceutical companies. Its primary therapy areas include cardiovascular (CVS) disease, central nervous system (CNS) disorders, diabetes, oncology, pain management (anti-migraine, analgesic) and anti-infectives (antibiotic). It also develops APIs in the therapeutic areas such as anti-fungal, anti-histaminic, anti-acne, anti-emetic, ophthalmologic agent, urinary and anti-spasmodic. It has a diversified portfolio of around 151 molecules & supplies its products to customers in India, Europe, North America, Latin America, Japan and the rest of the world. Its four manufacturing facilities are located in Ankleshwar, Dahej, Mohol and Kurkumbh with a total installed capacity of approximately 1198 KL.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
855.1 INR
Average target price
932.6 INR
Spread / Average Target
+9.06%
Consensus
  1. Stock Market
  2. Equities
  3. GLS Stock
  4. News Glenmark Life Sciences Limited
  5. Glenmark Pharmaceuticals to Sell 7.84% Stake in Glenmark Life Sciences